Q3 2025 · 13F-HR
Catalio Capital Management, LPholdings as filed
Filed 2025-11-14 · accession 0001958125-25-000009
$540.9M
Reported value
38
Positions
2025-09-30
Period end
The Brief · Catalio Capital Management, LP · Q3 2025
AI · grounded in 13F
Catalio Capital Management, LP exited its position in EW for a reduction of $30.6M. The fund established new positions in ABBV for $35.9M and REGN for $19.9M. Other notable activity includes closing positions in GILD and TEVA, while adding new stakes in ABVX and SUPN.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 532457108 | LLY | ELI LILLY & CO | $43.8M | 8.09% | 57,376 | Common | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $35.9M | 6.63% | 154,834 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $32.3M | 5.98% | 622,729 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $31.9M | 5.90% | 71,343 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $28.8M | 5.33% | 144,954 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $28.3M | 5.23% | 418,245 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $26.3M | 4.86% | 667,615 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $25.7M | 4.75% | 262,972 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $24.8M | 4.59% | 1,614,717 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $24.8M | 4.59% | 451,581 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $23.9M | 4.42% | 148,369 | Common | SOLE |
| 75886F107 | REGN | REGENERON PHARMACEUTICALS | $19.9M | 3.67% | 35,344 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $18.3M | 3.37% | 651,810 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $16.5M | 3.05% | 282,940 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $14.3M | 2.65% | 216,527 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $13.8M | 2.54% | 162,141 | Common | SOLE |
| 868459108 | SUPN | SUPERNUS PHARMACEUTICALS INC | $13.7M | 2.54% | 287,090 | Common | SOLE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $13.6M | 2.52% | 248,987 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $13.3M | 2.46% | 1,128,521 | Common | SOLE |
| 00650F109 | ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $13.2M | 2.45% | 884,890 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $11.5M | 2.12% | 263,256 | Common | SOLE |
| 000899104 | ADMA | ADMA BIOLOGICS INC | $10.0M | 1.86% | 684,508 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $8.8M | 1.62% | 291,262 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $8.3M | 1.53% | 5,214,236 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $8.2M | 1.51% | 137,928 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $6.5M | 1.21% | 1,500,793 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $5.5M | 1.02% | 294,360 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $5.1M | 0.94% | 53,333 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $3.5M | 0.65% | 586,909 | Common | SOLE |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $2.7M | 0.51% | 1,061,132 | Common | SOLE |
| 690145206 | OM | OUTSET MED INC | $1.7M | 0.31% | 118,279 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $1.3M | 0.23% | 528,993 | Common | SOLE |
| N0731H103 | ATAI | ATAI LIFE SCIENCES NV | $1.0M | 0.19% | 196,858 | Common | SOLE |
| 44916K106 | HYPR | HYPERFINE INC | $992,584 | 0.18% | 684,541 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $954,549 | 0.18% | 133,131 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $935,115 | 0.17% | 142,984 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $752,907 | 0.14% | 12,010 | Common | SOLE |
| 81728A207 | SNSE | SENSEI BIOTHERAPEUTICS INC | $139,085 | 0.03% | 14,718 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.